In a single stroke, the Indian Patent Office set the dominoes falling on 11 August when it granted $53-billion pharma major Pfizer a patent for a vaccine that can prevent pneumonia. On 28 September, Panacea Biotec was the first to cry foul. After working for over a decade, it was close to a breakthrough, planning to launch its own Pneumococcal Conjugate Vaccine (PCV) by 2020. It was relying on the government to buy its affordable version over Pfizer’s expensive one.

Pneumonia and such influenza infections lead to 5% of all deaths in India.


Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Sign up to our India edition to read this story instantly

To sign up, you’ll create an account that will give you access to a new free story published once a week and archive of 214+ previously published free stories from our India edition. You’ll also receive one email every morning from us introducing the day’s story.

If you’ve already signed up, just enter your email below or login using Facebook or Google.